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Abstract: Chemotherapy alone has limited ability to significantly improve survival in 
non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth 
factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two 
classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the 
intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the 
extracellular domain in the ligand-binding region. Cetuximab is a human – mouse chimeric 
immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies 
with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. 
Cetuximab is currently the focus of intense investigation in various patient populations with 
NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future 
directions with this agent.
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Introduction
Lung cancer is the most common cause of cancer death in both men and women in 
the United States and around the world.1,2 Approximately 85% of lung cancers are 
non-small cell lung cancers (NSCLC), and approximately 75% of these are meta-
static at diagnosis.3,4 While therapy has evolved over the last few decades and has 
repeatedly been shown to improve survival, the five-year overall survival of patients 
with NSCLC is a dismal 15%.2 The significant toxicity associated with cytotoxic 
chemotherapy also excludes a number of patients based on age, co-morbidities, or 
poor performance status.5
Platinum-based doublets have been established therapy for metastatic NSCLC 
since the mid-1990s.6 Numerous studies have shown that, among cytotoxic chemo-
therapeutics, two-agent therapy is more effective than single-agent therapy.7–9 Using 
three or more cytotoxic therapies does not improve efficacy and increases toxicity.10,11 
Commonly used chemotherapy doublets incorporate cisplatin or carboplatin with 
agents that include paclitaxel, docetaxel, vinorelbine, gemcitabine, or more recently 
pemetrexed. Many regimens given in the first-line setting result in a median survival 
time of eight to 10 months, with one- and two-year survival rates of 35% to 45%, and 
10% to 20%, respectively.12
While studies with new chemotherapeutic agents are ongoing, evidence now 
available suggests that chemotherapy alone has limited ability to significantly 
improve survival beyond what has already been achieved.13 Furthermore, toxicities Biologics: Targets & Therapy 2009:3 216
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associated with these medicines not only exclude some 
patients based on poor performance status but also pre-
clude a number of patients from completing chemotherapy 
courses as scheduled at the full therapeutic dose.5 As the 
knowledge of tumor biology has improved, biologic agents 
that specifically target molecules thought to be critical to 
tumorigenesis have emerged. Theoretically, the greater 
specificity against malignant cells with targeted agents 
should result in simultaneously greater efficacy and less 
toxicity, thereby allowing usage in patients previously 
excluded from consideration of systemic therapy.
Biologic therapies targeting the vascular endothelial 
growth factor receptor (VEGFR) and the endothelial 
growth factor receptor (EGFR) are undergoing evaluation 
to determine their potential role in NSCLC.13 Bevacizumab, 
a monoclonal antibody against VEGFR,14 and erlotinib, 
a small molecule inhibitor of the intracellular tyrosine 
kinase of   EGFR,15 currently are indicated for use in NSCLC. 
Cetuximab, a monoclonal antibody against EGFR, is currently 
being studied extensively. Here we review the role of 
cetuximab in the treatment of NSCLC.
EGFR in lung cancer
EGFR, whose ligands include epidermal growth factor (EGF) 
and transforming growth factor-alpha (TGF-α), is a member 
of the ErbB1 (HER-1) family of receptors.16,17 Binding of the 
extracellular domain by EGF or TGF-α induces dimerization 
of EGFR, leading directly to activation of kinase activity in 
the intracellular domain. Receptor tyrosine kinases transfer 
phosphate groups from bound ATP to tyrosine residues on 
the carboxy (C) terminal portion of the receptor.18,19 Multiple 
intracellular cascades are activated when adaptor molecules 
recognize phosphotyrosines on the C-terminal of EGFR: 1. 
KRAS/RAF/MEK/MAP kinase pathway via binding of 
Grb2/SOS; 2. PI3-K pathway and the 3. STAT3/5 pathway20 
(Figure 1). The complexity (ie, pathway overlap and crosstalk) 
of intracellular signaling via tyrosine kinases is vastly oversim-
plified by a cursory discussion, but it is evident that activation 
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Figure 1 EGFR signaling pathway.   The figure depicts the downstream pathways following activation of the EGF receptor. Binding of a ligand to the receptor activates the tyrosine 
kinase (K) which then activates the downstream signaling pathways that eventually lead to increased proliferation, cell cycle progression and decreased apoptosis. Solid arrows 
indicate stimulation, while dashed arrows indicate suppression. Sites of action of the tyrosine kinase inhibitors (TKis) and monoclonal antibodies are also shown.
Abbreviations: eGFR, endothelial growth factor receptor; Pi3K, phosphoinositide-3-kinase; STAT, signal transducer and activator of transcription; JAK, Janus kinase; pAKT, 
phospho AKT; MAPK, mitogen-activated protein kinase.Biologics: Targets & Therapy 2009:3 217
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of these pathways serves to increase transcription and cellular 
proliferation, and inhibit apoptosis.20 In malignant cells, they 
also contribute to angiogenesis and metastasis.21,22
The EGF pathway plays a vital role in the pathogenesis 
and progression of NSCLC. Approximately 50%–80% of 
NSCLC demonstrate overexpression of EGFR activity.23–27 
Although the majority of NSCLC overexpress EGFR at 
diagnosis, expression appears to vary with histology (65% in 
adenocarcinomas to 84% in squamous carcinomas).28 EGFR 
expression also seems to correlate with stage at presentation. 
EGFR levels are higher in pathological stage IV NSCLC than 
in stage I and II disease and higher in cases with mediastinal 
involvement than in cases without it.29
Although EGFR expression is important in the devel-
opment and progression of malignancy, its prognostic 
significance is unclear. Some studies observed a correla-
tion between EGFR expression and tumor invasiveness,30 
and poorer survival,31–33 while there was no relation seen in 
another study.25 EGFR amplification in a subset of patients 
from the INTACT trials34,35 appeared to correlate with a 
response to gefitinib (Iressa®; AstraZeneca, Wilmington, 
DE); but no effect on overall survival was seen.36 In a meta-
analysis of 2792 patients enrolled in 18 different studies, 
Nakamura and colleagues found that EGFR overexpression 
had no impact on survival in patients with NSCLC (hazard 
ratio [HR], 1.14; 95% confidence interval [CI]: 0.97–1.34; 
p = 0.1).37 Other studies however found that not only is EGFR 
expression increased in NSCLC, but its presence is associated 
with poor prognosis.30–32,38
Various mechanisms for upregulation of receptor activity 
in NSCLC have been discovered:
•  Increased production of EGFR with or without increased 
EGFR gene copy number39
•  EGFR mutations resulting in constitutive activation of 
the receptor, regardless of ligand binding39,40
•  Increased production of ligands, TGF-α, or EGF or 
related proteins.24
The most common clinically relevant assays for EGFR 
expression in NSCLC include assays for gene amplification,41 
immunohistochemical (IHC) stains for protein overexpression,42 
and detection of specific mutations by DNA sequencing.43 
EGFR copy number can be measured using fluorescence 
in situ hybridization (FISH),44 while EGFR mutations can be 
detected using sequencing analyses of DNA.45
Targeted agents against EGFR
Two classes of drugs inhibiting the EGFR pathway are 
currently in clinical usage: small molecules that inhibit the 
intracellular tyrosine kinase activity of the receptor, and 
monoclonal antibodies that target the extracellular domain 
in the ligand-binding region. Gefitinib (Iressa®; AstraZeneca) 
and Erlotinib (Tarceva®; OSI Pharmaceuticals, Inc. Melville, 
NY) are the two most studied drugs in the EGFR-tyrosine 
kinase inhibitor class. Canertinib (C11033), lapatinib 
(GW572016, Tykerb®; GlaxoSmithKline, Research Triangle 
Park, NC), PKI166, and EKB569 are examples of other drugs 
in this class currently in development. The most well known 
EGFR monoclonal antibody is cetuximab (Erbitux®; Bristol-
Myers Squibb Company, Princeton, NJ). Panitumumab 
(AMG706, Vectibix®; Amgen Inc., Thousand Oaks, CA), 
matuzumab (EMD7000), and nimotuzumab (h-R3) are EGFR 
monoclonal antibodies currently being developed.
Clinical trials of tyrosine  
kinase inhibitors
Gefitinib
Gefitinib was the first EGFR-TKI tested in clinical trials. 
Two phase II trials (IDEAL-1 and IDEAL-2) showed that 
gefitinib produced a response rate of 9%–18% and overall 
disease control rate of 43%–50% in patients with relapsed 
NSCLC.46,47 However the phase III ISEL trial that random-
ized nearly 1700 patients with advanced NSCLC to gefitinib 
or placebo, failed to reveal an overall survival benefit.48 
A recent phase III trial (INTEREST) showed that gefitinib was 
noninferior to docetaxel in terms of overall survival (OS) in 
patients with relapsed NSCLC; it was also better tolerated and 
correlated with better quality of life.49 Similarly, another ran-
domized phase II study comparing gefitinib with vinorelbine 
in chemo-naïve elderly patients with advanced non-small-cell 
lung cancer found that gefitinib had similar response rates and 
progression-free (PFS) and overall survival to vinorelbine.50
Two trials (INTACT-1 and INTACT-2) trials that com-
bined gefitinib with chemotherapy in the first-line setting,34,35 
did not show any survival benefit from the addition of gefitinib. 
On the other hand, although the IPASS (Iressa Pan-Asia 
Study) comparing gefitinib with carboplatin/paclitaxel for pre-
viously untreated Asian never- or light-smokers with advanced 
adenocarcinoma found no difference in overall survival,51 
patients who had EGFR gene mutations had a greater response 
rate (71.2% vs 41.3%) and improved overall survival (HR, 
0.48; 95% CI: 0.36–0.64; p  0.0001) with gefitinib.
erlotinib
Unlike gefitinib, erlotinib has shown clinical efficacy that has 
resulted in its unrestricted US Food and Drug Administration Biologics: Targets & Therapy 2009:3 218
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(FDA) approval in NSCLC. BR21, a randomized phase III 
trial of 731 patients with stage IIIB or IV NSCLC showed 
that patients randomized to erlotinib had a statistically signifi-
cant increase in overall survival, PFS, and overall response 
rate.15 However, similar to the results seen with gefitinib, 
phase III trials evaluating the combination of a platinum-
based doublet alone or with erlotinib, gemcitabine – cisplatin 
(TALENT)52 and carboplatin – paclitaxel (TRIBUTE)53 
did not show any advantage to the addition of erlotinib.
Cetuximab
introduction
Cetuximab is a human-mouse chimeric immunoglobulin 
G1 (IgG1) class monoclonal antibody directed against 
the EGFR with proven second- or third-line efficacy in 
colorectal54 and head and neck cancers.55,56 This monoclonal 
antibody binds to the extracellular ligand-binding domain 
with affinity five times greater than natural ligands like 
TGF-α and EGF.57 Binding of cetuximab prevents dimer-
ization and subsequent activation by auto-phosphorylation 
of the receptor in the intracellular kinase domain.58 The 
receptor-antibody complex is internalized and degraded, 
thereby decreasing EGFR availability.59 In vitro studies 
show the antibody also mediates antibody-dependent 
cellular cytotoxicity (ADCC) against the receptor.60
Preclinical studies with cetuximab suggested that there 
was inhibition of growth of human NSCLC cell lines and 
other EGFR-expressing cell lines in vitro61–63 and in athymic 
nude mice,61,63 and combinations with cytotoxic agents 
produced synergistic greater delay of tumor growth.63,64 In 
addition, cetuximab had a potentiating effect on the growth 
delay produced by radiotherapy.65
Doody and colleagues studied the activity of cetux-
imab with NSCLC lines bearing both wild-type EGFR 
and those with activating mutations in the intracellular 
kinase domain: not only those known to confer sensitivity 
to gefitinib and erlotinib (L858R and delL747-T753insS) 
but also the TKI-resistant mutation T790M.66 They 
found that ligand-independent phosphorylation of the 
T790M lines was unaffected by cetuximab (as measured 
by assays for phosphorylated EGFR, and downstream 
phosphorylated molecules Akt and MAPK) and cellular 
proliferation was inhibited. Previous studies had shown 
that binding of EGFR antibodies to wild-type EGFR 
resulted in increased internalization and degradation 
of the receptor-antibody complex without stimulating 
phosphorylation of the receptor.67 Similarly, Doody and 
colleagues demonstrated that mutant EGFR (including 
T790M) was internalized and degraded at a higher rate than 
wild-type EGFR.66
Clinical trials
Given the promising results of these preclinical experiments, 
cetuximab was introduced into clinical trials. While cetux-
imab was generally well tolerated, the common side effects 
seen in phase I testing included: skin toxicity, nausea, fever/
chills, asthenia, and elevation of transaminases; grade 3 or 
4 toxicities included dyspnea, aseptic meningitis, anaphy-
lactoid reaction, diarrhea, and epiglottitis.68
First-line therapy
A phase I/II trial combining cetuximab with paclitaxel/
carboplatin produced 65% overall disease control rate (partial 
response [PR], 26%; stable disease, 39%).69 Median PFS, 
OS, and one-year survival were 5 months, 11 months, and 
40%, respectively. Similar results were seen when cetuximab 
was combined with gemcitabine and carboplatin (PR 28%; 
stable disease, 60%; median PFS, 5.3 months; median OS, 
10.3 months; one-year survival, 45%).70 A randomized 
phase II study comparing vinorelbine/cisplatin with the same 
chemotherapy plus cetuximab71 suggested that addition of 
cetuximab led to better outcomes (odds ratio [OR], 35% vs 
28%; median PFS, 5.0 vs 4.6 months; median OS, 8.3 vs 7.3). 
Similar results were seen in another randomized phase II 
study of gemcitabine plus cisplatin or carboplatin with or 
without cetuximab. Although the study design was non-
comparative, addition of cetuximab seemed to improve out-
comes in terms of PR (27.7% vs 18.2%), median PFS (5.1 vs 
4.2 months), and median OS (11.99 vs 9.26 months).72
The results of these trials led to the conduct of the phase III 
FLEX trial,73 which randomized 1125 patients with EGFR 
overexpressing advanced NSCLC to cisplatin/vinorelbine 
with or without cetuximab. The basis for patient selection in 
this trial was presence of the EGFR staining by IHC, which 
the investigators defined as the presence of at least one 
EGFR-positive cell. This is the first study that has used IHC 
to determine eligibility for EGFR-targeted therapy.
Addition of cetuximab led to a significant improve-
ment in overall survival (11.3 vs 10.1 months; HR, 0.871; 
P = 0.0441). One-year survival also was higher in the cetux-
imab group (47% vs 42%). Interestingly however there was 
no difference in PFS between the two groups. Though the 
benefit with the addition of cetuximab was modest, the results 
of this trial led to cetuximab being incorporated into the 
National Comprehensive Cancer Network (USA) guidelines 
for use in the first-line setting in combination with cisplatin Biologics: Targets & Therapy 2009:3 219
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and vinorelbine (see http://www.nccn.org/professionals/
physician_gls/PDF/nscl.pdf).
Preliminary results of pre-specified subgroup analyses 
suggest a greater benefit with the addition of cetuximab in 
Caucasians. Caucasian patients who received cetuximab had 
a median survival of 10.5 months as opposed to 9.1 months in 
those who did not receive cetuximab (HR, 0.8; P = 0.0025). 
However although Asians had a better prognosis in general, 
there was no additional benefit to the addition of cetuximab. 
Median survival in the cetuximab group among Asians was 
17.6 months as compared to 20.4 months in the placebo group 
(HR, 1.179; P = 0.4992).
Second-line therapy
Single agent cetuximab seems to result in outcomes similar to 
docetaxel, pemetrexed or erlotinib in patients with recurrent 
or progressive NSCLC,74 all of which are currently approved 
for the treatment of patients with NSCLC, who have failed 
first-line therapy. In this study by Hanna and colleagues, 
although the response rate was only 4.5% (3/66), 30.3% 
of patients had stable disease. Moreover, median time to 
progression and median OS were 2.3 and 8.9 months, respec-
tively, and one-year survival was 43.9%, values numerically 
similar to those seen in studies with erlotinib, pemetrexed, 
and docetaxel. In the second-line setting, cetuximab was 
combined with docetaxel75 and demonstrated a response rate 
of 25% among 20 patients with minimal toxicities.
Combination with chemoradiotherapy
Positive results for the radio-sensitizing effects of cetuximab 
in head and neck cancer55 led investigators to test cetuximab in 
combination with synchronous radiotherapy following induc-
tion chemotherapy in chemotherapy-naïve stage III NSCLC 
patients.76 The toxicity results published thus far suggest that 
this is a safe regimen. The Cancer and Leukemia Group B 
(CALGB) conducted a randomized phase II study of thoracic 
radiation (70 Gy) along with carboplatin and pemetrexed 
for four cycles (arm A) or the same chemotherapy regimen 
along with cetuximab for additional six weeks (arm B). 
Subsequently all patients received four additional cycles 
of pemetrexed as consolidation therapy. The main adverse 
effects were hematologic with grades 3/4 neutropenia seen 
in 36% and 37% patients in arms A and B respectively and 
grades 3/4 thrombocytopenia in 30% and 34% of patients. 
Esophagitis (35% and 22%), fatigue (22% and 18%) and skin 
rash (3% and 22%) were the most common nonhematologic 
toxicities. These initial results suggest acceptable tolerability. 
Efficacy results of this study are awaited.
Currently, multiple studies are currently underway 
evaluating the role of cetuximab in different patient popula-
tions with NSCLC (Table 1). The results of these studies 
should help us understand the exact role of cetuximab in the 
treatment of NSCLC.
Targeting EGFR inhibitors
One of the major issues in the use of EGFR-targeted therapy 
in NSCLC has been the identification of patients who would 
actually benefit from these agents. Identifying predictive 
markers for a response to the EGFR-targeted therapy has been 
quite challenging. Most of the available information focuses 
on response to EGFR TKIs rather than cetuximab, since these 
agents have been in use for a longer period of time.
Clinical factors that can help predict response to EGFR 
TKIs have been investigated. A subset analysis of the 
BR21 trial showed that women, nonsmokers, patients with 
adenocarcinoma and patients with Asian ethnicity had better 
outcomes with erlotinib.15 A subset analysis of the IDEAL-1 
trial47 revealed that patients with adenocarcinoma had supe-
rior outcomes, despite the observation that high EGFR 
expression is more common in squamous cell carcinomas 
than in adenocarcinomas.77 Mutation studies of the EGFR 
gene showed that somatic mutations in the tyrosine kinase 
domain of the EGFR gene predicted for response to gefitinib 
and were associated with an improved outcome.36,78–80
Correlative studies from the ISEL trial showed that a 
high EGFR gene copy number was a predictor of clinical 
benefit from gefitinib.81 Patients whose tumors expressed 
the EGFR protein and who were treated with gefitinib 
had a slightly greater survival advantage (HR, 0.77; 95% 
CI: 0.56–1.08; P = 0.126). Also, patients with EGFR 
mutations had higher response rates than patients without 
EGFR mutations (37.5% vs 2.6%). In another analysis of 
204 patients treated with gefitinib, Hirsch and colleagues 
found that although increased EGFR and HER2 gene copy 
number, EGFR protein overexpression, EGFR mutations, 
and pAKT overexpression were all associated with signifi-
cantly higher response rates only increased EGFR gene 
copy number and EGFR protein overexpression correlated 
with improved survival.82 In similar studies on samples 
from patients treated with erlotinib, there was no asso-
ciation between the presence of EGFR mutations and 
responsiveness to erlotinib. However similar to the findings 
of Hirsch and colleagues, in this analysis, expression of 
EGFR and an increased number of copies of EGFR were 
associated with responsiveness to erlotinib but not with 
increased survival.83Biologics: Targets & Therapy 2009:3 220
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Table 1 Current or planned trials of cetuximab in non-small cell lung cancer
Name/ID Population Phase Interventions
NCT00112294 Advanced or metastatic, 
chemotherapy naïve
iii Taxane + carboplatin ± cetuximab
NCT00097214 Stage iiiB/iv ii Carboplatin + cetuximab
NCT00097227 Stage iiiB/iv ii Carboplatin + paclitaxel + cetuximab
NCT00112346 Stage iiiB/iv ii Gemcitabine + platinum ± cetuximab
NCT00118183 Stage iiiB/iv ii Docetaxel + cetuximab or bortezomib
NCT00368992 Stage iiiB/iv ii Cetuximab + paclitaxel + carboplatin + bevacizumab; 
maintenance cetuximab + bevacizumab
NCT00343291 Stage iiiB/iv or recurrent 
chemotherapy naïve
ii Cetuximab + paclitaxel + carboplatin + bevacizumab; 
maintenance cetuximab + bevacizumab
NCT00027755 Treatment naïve stage iv ib/iia Cetuximab + gemcitabine + carboplatin
NCT00193453 Unresectable stage iii/iv ii Cetuximab + gemcitabine + docetaxel
CALC-1 Advanced ii Cetuximab + gemcitabine
NCT00251498 Advanced ii Carboplatin + docetaxel + cetuximab
NCT00315185 Advanced ii Cetuximab
NCT00408499 Advanced ii erlotinib + cetuximab
NCT00561054 Advanced ii Cetuximab + cisplatin + gemcitabine
NCT00828841 Advanced ii Cetuximab + either carboplatin + paclitaxel or  
platinum + gemcitabine/pemetrexed
NCT00842712 Advanced ii Cilengitide + cetuximab + platinum-based 
chemotherapy
NCT00165334 elderly, treatment naïve, advanced ii vinorelbine + cetuximab
NCT00673738 Locally advanced, poor PS, elderly ii Cetuximab + conformal thoracic radiotherapy
NCT00820755 Maintenance ii Cetuximab maintenance following platinum-based 
therapy
NCT00716456 Adenocarcinoma with acquired 
resistance to erlotinib
ii erlotinib + cetuximab
NCT00694603 Progression on TKi ii Cetuximab
NCT00063388 Recurrent ii Cetuximab
NCT00103207 Recurrent ii Cetuximab
NCT00162318 Recurrent i Gefitinib + cetuximab
NCT00216203 Recurrent i/ii Pemetrexed + cetuximab
NCT00095199 Recurrent/progressive iii Docetaxel vs cetuximab
NCT00118118 Recurrent/progressive ii Cetuximab
NCT00203931 Recurrent/progressive ii Cetuximab or cetuximab + pemetrexed
NCT00519831 Second-line ii Vinflunine + cetuximab
NCT00115518 Stage iii ii Cetuximab + radiation
NCT00124618 Stage iii ii Cetuximab + radiation
NCT00288054 Stage iii i Docetaxel + cetuximab + radiation
NCT00522886 Stage iii i Carboplatin + gemcitabine followed by cetuximab + 
radiation + cisplatin + vinorelbine
NCT00533949 Stage iii ii Carboplatin + paclitaxel ± cetuximab + either 
standard or high-dose radiation
NCT00081302 Stage iiiA ii Carboplatin + paclitaxel + cetuximab + radiation
NCT00492206  Stage iiiA/iiiB  ii  Cetuximab + radiation followed by consolidation 
chemotherapyBiologics: Targets & Therapy 2009:3 221
Cetuximab in lung cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Three retrospective studies from Japan and Korea, where 
the somatic EGFR mutations are detected approximately 
thrice as common than in the United States and Europe have 
shown that response rates following treatment with gefitinib 
in patients with EGFR mutations ranged from 65%–83% as 
compared to 10%–15% for those without the mutations.84–86 
This translated into an overall survival advantage for treat-
ment with gefitinib in patients with the mutations.
Hirsch and colleagues analyzed tissue samples from 
patients enrolled onto a phase II trial of paclitaxel/carboplatin 
with either sequential (cetuximab weekly for one year follow-
ing the completion of chemotherapy) or concurrent (weekly 
cetuximab during and for one year following chemotherapy) 
cetuximab therapy for EGFR status.87 Progression free 
survival and disease control rate (DCR) were statistically 
significantly better in FISH (+) patients, and there was a 
nonsignificant trend toward higher objective response rate 
(ORR) as compared to FISH (-) patients in both arms. The 
authors concluded that EGFR FISH status is a predictive 
factor for selection of NSCLC patients for cetuximab plus 
chemotherapy. Critics point out many potential flaws in 
attempting to draw conclusions based on these results and 
urge caution in interpreting them.88
Although EGFR-targeted therapies have been approved 
for use without molecular testing, immunohistochemistry 
to detect EGFR protein overexpression, fluorescence in situ 
hybridization to detect EGFR gene amplification, and muta-
tional analyses of the EGFR gene have all been proposed as 
candidates to help predict benefit from EGFR-directed therapy 
in NSCLC. In fact the FLEX trial was the first to incorporate 
the presence of EGFR positivity as an inclusion criterion for the 
study.73 However even in this trial, a rather loose definition of 
EGFR positivity was employed; patients who had even one cell 
staining for EGFR by IHC were considered EGFR positive.
As is evident from the disparity in the results from the 
studies discussed above, there is an urgent need for standard-
ization of these assays. Without such standardization, routine 
utilization of these technologies to guide clinical decision 
making in a given patient will be difficult. In order to address 
this issue the Molecular Assays in NSCLC Working Group 
was convened under the sponsorship of Genentech Inc, Roche 
Pharmaceuticals, and OSI Pharmaceuticals, Inc, to evaluate 
the available molecular assays for use in the clinical trial 
setting and provide recommendations for application and 
interpretation of these tests.89 The recommendations from 
this group included the following:
•  At least three representative areas should be assessed per 
tumor section.
•  The minimum cell number to be evaluated should 
be: FISH: 100 assessable tumor cell nuclei, IHC/mutation: 
2,000 cells, Direct sequencing -50%–70% tumor cells.
•  Standardization of molecular assays:
  Kit-based antibodies preferred for immunohistochem-
istry, with a simple standard scoring system needed.
  FISH: Two-color FISH with CEP® control, using the 
Colorado scoring system.90
  Mutational analysis: Direct sequencing; replicate PCR 
and sequencing reactions to establish mutation status 
of each sample amplicon.
The tumor biology of NSCLC prevents easy answers. 
Unlike CML that relies almost exclusively on the tyrosine 
kinase activated by the fusion Bcr-Abl,91 or a closer analogy, 
the overexpression of  HER-2 in 25%–30% of  breast cancers,92 
carcinogenesis of NSCLC is not so heavily dependant on 
EGFR status (by any measure of EGFR). The absence of this 
“oncogene addiction”93 in NSCLC illustrates why patients 
with NSCLC will continue to require multimodal therapy for 
the foreseeable future.
Future directions
It is likely that the lessons on how to use cetuximab wisely 
may come from experience in patients with colon cancer. 
RAS is one of the downstream signaling molecules stimu-
lated by active EGFR. Mutations that cause constitutive 
activation of the K-RAS oncogene predict resistance to 
cetuximab in colorectal cancer (CRC) cell lines.94 This 
study emerged in the wake of retrospective observations that 
patients who failed to respond to cetuximab were more likely 
to have mutated, constitutively activated K-RAS,95,96 although 
some studies observe good clinical response in patients 
with mutated K-RAS.97 A recently published study noted a 
mutation in the extracellular domain (R521K of exon 13) of 
EGFR that predicted response to cetuximab.97
However these observations must be made with the caveat 
in mind that tumor biology of colon cancer is different from 
NSCLC. Somatic mutations in EGFR are almost never seen in 
CRC cell lines.98 Also cetuximab activity in colorectal cancer 
does not correlate with EGFR protein levels as measured by 
IHC54,99 but does correlate with gene copy number measured 
by FISH.100 Despite this, multiple trials in NSCLC have shown 
that mutant K-RAS predicts resistance to erlotinib.101,102
Future investigations should stratify patients with respect 
to EGFR status and other potential predictive factors like 
K-RAS mutations. Future studies should address the predictive 
markers for cetuximab activity, be it gene amplification by 
FISH or protein overexpression by IHC or mutation analysis. Biologics: Targets & Therapy 2009:3 222
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Also studies should be conducted to determine if cetuximab 
is useful in patients who have already failed an EGFR-TKI.
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